Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 806 of 6351
-
New pill takes on brain tumors and metastases in early trial
Disease control Recruiting nowThis multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 alone for the treatment of patients with radiographically-confirmed progression of Astrocytoma IDH- mutant, Glioblastoma ID…
Phase 1/2 • Sponsor: Neonc Technologies, Inc. • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Promising combo aims to boost remission in follicular lymphoma
Disease control OngoingThe goal of this study is to learn about the safety and effectiveness of the combination of tazemetostat pills in combination with mosunetuzumab injections for people with follicular lymphoma who haven't received treatment before. The investigators hypothesize that tazemetostat w…
Phase 2 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New 'Four-in-One' antibody takes on tough lymphoma
Disease control Recruiting nowPhase I main objectives: To observe the safety and preliminary efficacy of GNC-035 in patients with relapsed/refractory non-Hodgkin lymphoma and other hematological malignancies, to determine the DLT and MTD, or MAD, and to determine RP2D. Phase II Main objective: To explore the …
Phase 1/2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Can a One-Hour chat help teens at risk for suicide?
Symptom relief CompletedThe current study is a clinical trial, meaning a research study in which human subjects are prospectively assigned to one or more interventions to evaluate the effects of those interventions on health-related behavioral outcomes. Specifically, male and female adolescents with cur…
Sponsor: Ohio State University • Aim: Symptom relief
Last updated Jun 27, 2026 11:02 UTC
-
Can a heart drug tame blood sugar and weight in diabetes?
Disease control Completed1. Evaluating the effect of nicorandil on glycemic control of diabetic obese patients treated with sulfonylureas. 2. Investigating the effect of nicorandil on body weight of diabetic obese patients treated with sulfonylureas.
Phase 2 • Sponsor: Tanta University • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New TB drug cocktail aims to shorten treatment
Disease control OngoingThe goal of this clinical trial is to evaluate 3 dose levels of TBAJ876 for 8 weeks in combination with pretomanid and linezolid, compared to 8 weeks of Isoniazid, rifampicin, pyrazinamide and ethambutol (2HRZE), in adult participants with newly diagnosed, smear-positive, pulmona…
Phase 2 • Sponsor: Global Alliance for TB Drug Development • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New psoriasis drug shows promise in chinese trial
Disease control CompletedThe primary purpose of this study is to compare the efficacy of bimekizumab administered subcutaneously (sc) for 16 weeks versus placebo in the treatment of study participants with moderate to severe plaque psoriasis (PSO).
Phase 3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New device aims to block tubes without surgery
Disease control Recruiting nowProspective, multi-center, international, unblinded, single-arm trial of subjects undergoing FemBloc followed by ultrasound confirmation test.
Sponsor: Femasys Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Ancient chinese herb berberine tested to stop heart disease and diabetes in its tracks
Prevention OngoingThis multicenter, double-blinded, randomized controlled trial aims to evaluate the effect of berberine on preventing cardiovascular disease and diabetes mellitus among individuals with high cardiometabolic risk in China.
Phase 4 • Sponsor: China National Center for Cardiovascular Diseases • Aim: Prevention
Last updated Jun 27, 2026 08:07 UTC
-
New drug combo shows promise for hard-to-treat lymphoma
Disease control Recruiting nowSubjects with relapsed large cell lymphoma will receive 3 cycles of combination therapy consisting of GDP and epcoritamab. Each cycle will last 21 days. GDP consists of gemcitabine 1000 mg/m2 IV on Days 1 and 8, cisplatin 75 mg/m2 IV on Day 1, and dexamethasone 40 mg orally on Da…
Phase 2 • Sponsor: Dipenkumar Modi • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Can a year of immunotherapy stop kidney cancer from spreading after radiation?
Disease control Recruiting nowTo learn if adding 1 year of therapy with pembrolizumab can help to continue to control RCC after radiation therapy.
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Could a heart pill help fontan teens breathe easier during exercise?
Disease control Recruiting nowThis study will evaluate the clinical efficacy and safety of udenafil, an orally administered, potent and selective inhibitor of PDE5, versus placebo for the treatment of adolescent who have had the Fontan procedure.
Phase 3 • Sponsor: Mezzion Pharma Co. Ltd • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New drug combo aims to shrink tough lung cancers
Disease control OngoingPhase Ib: To observe the safety and tolerability of the combination of SI-B001 and SI-B003, and to determine the recommended dose of phase II clinical study (RP2D) in the indication of locally advanced or metastatic non-small cell lung cancer. Phase II: To evaluate the efficacy o…
Phase 1/2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Single Nerve-Freezing treatment could replace opioids for broken ribs
Symptom relief By invitation onlyThoracic trauma frequently involve rib fractures which can be very painful for 2-3 months. Unfortunately, pain is not simply a "symptom" of the injuries, but a significant cause of additional medical problems: pain causes people to breath and cough less deeply/often which increas…
Sponsor: University of California, San Diego • Aim: Symptom relief
Last updated Aug 26, 2026 00:00 UTC
-
Double immune attack: can two drugs save Insulin-Making cells in new diabetes?
Disease control OngoingThe study is a two-arm, multicenter, double-blinded clinical trial testing sequential therapy with rituximab-pvvr followed by abatacept versus rituximab-pvvr alone in new onset T1D. The primary objective is to test whether the C-peptide response to a 2-hour mixed meal tolerance t…
Phase 2 • Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Promising new eye treatment could halt vision loss from keratoconus
Disease control CompletedA Multicenter, Randomized, Double-Masked, Sham-Controlled, Parallel-Group Phase 3 Study to Evaluate the Efficacy and Safety of Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With Keratoconus
Phase 3 • Sponsor: Epion Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Which dialysis dose saves more lives in the ICU? a trial seeks answers
Disease control Recruiting nowThis clinical trial aims to investigate whether the low treatment intensity (12 mL/kg/hr, low-dose hemodialysis/filtration) or the medium treatment intensity (25 mL/kg/hr, standard-dose hemodialysis/filtration) is more effective and safer for continuous renal replacement therapy …
Phase 2/3 • Sponsor: Jikei University School of Medicine • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Which dialysis method works best for ICU kidney failure? a Head-to-Head test
Disease control Stopped earlyIntermittent hemodialysis (IHD) and continuous RRT (CRRT) provided as continuous hemofiltration or hemodiafiltration are the main RRT modalities in ICU. Randomized controlled trials (RCTs) comparing IHD and CRRT for AKI have not shown an indisputable benefit of one technique over…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
New drug combo aims to boost immunotherapy for head and neck cancer
Disease control OngoingThis is a phase 2 study investigating the efficacy of ramucirumab in combination with pembrolizumab compared to pembrolizumab monotherapy. Ramucirumab is a VEGFR-2 inhibitor believed to potentially enhance the efficacy of PD-1 inhibitors such as pembrolizumab.
Phase 2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New vaccine targets aggressive brain tumors in early trial
Disease control OngoingThis is a single institution, open-label, multi-arm, phase I study assessing the safety and immunogenicity of a personalized neoantigen-based personalized DNA vaccine combined with PD-1 blockade therapy in subjects with newly diagnosed, MGMT promoter unmethylated glioblastoma (GB…
Phase 1 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC